The clinical outcome of breast cancer and the survival of the women affected depend on some extensively studied prognostic factors, such as: the presence of lymph node metastases, the size and histological type of the tumor, its nuclear grade, the estrogen (ER) and progesterone (PR) hormone receptor status, the presence of the Human Epidermal growth factor Receptor 2 (HER-2) oncogene and the tumor cell proliferation.1 This evidence concerns the gene ESR1 and neoplasm.